Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 0.7823 USD 0.49% Market Closed
Market Cap: 42.7m USD

Spero Therapeutics Inc
Investor Relations

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

Show more
Loading

Earnings Calls

2024 Q4
Feb 21, 2025
Show Transcript
Previous
Next
Fibra Danhos Reports Strong Growth and Continued Expansion Plans
2024 Q4
Feb 21, 2025

In its fourth quarter of 2024, Fibra Danhos showcased robust performance, with double-digit growth in revenue, NOI, and EBITDA driven by improved occupancy and new tenant agreements. AFFO reached MXN 1.2 billion, resulting in a distribution of MXN 0.45 per CBFI, maintaining a 60% payout ratio. Their leverage stands at a solid 12.4%, supporting future expansion, particularly in industrial developments like Cuautitlán I. A notable new retail project in Oaxaca is expected to span 60,000 square meters, with a three to three-and-a-half-year timeline for development. Management projects stable dividends for investors while strategically investing in growth.

Show Full Analysis

Management

Dr. Ankit Mahadevia M.D., MBA
Co-Founder & Chairman of the Board
No Bio Available
Mr. Satyavrat Shukla C.F.A.
President, CEO & Director
No Bio Available
Mr. Timothy Keutzer
Chief Operating Officer
No Bio Available
Ms. Esther P. Rajavelu
CFO, Chief Business Officer & Treasurer
No Bio Available
Mr. James P. Brady
Chief Human Resource Officer
No Bio Available

Contacts

Address
MASSACHUSETTS
Cambridge
675 Massachusetts Ave Ste 14
Contacts